Reduction of Tendon Fibrosis Using Galectin-3 Inhibitors

Amanda F Spielman1, Michelle F Griffin1, Ashley L Titan1

  • 1From the Hagey Laboratory for Pediatric Regenerative Medicine and Department of Surgery, Division of Plastic and Reconstructive Surgery.

Abstract

Insights

This study developed a mouse model for tendon fibrosis and found that a galectin-3 inhibitor (Gal3i) can reduce fibrosis and scarring after tendon injury, offering a potential treatment for healing.

Area of Science:

  • Biomedical Engineering
  • Orthopedics
  • Regenerative Medicine

Background:

  • Tendon injuries and repairs can lead to fibrosis, impacting healing and function.
  • Adhesion formation post-injury reduces tendon strength and increases reinjury risk.
  • Understanding tendon fibrosis mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To establish a reproducible mouse model for assessing tendon fibrosis.
  • To identify potential antifibrotic agents for tendon injury repair.
  • To investigate the role of galectin-3 in tendon fibrosis.

Main Methods:

  • A mouse model was created by inducing Achilles tendon injury and abrasion.
  • Histologic and immunofluorescent analyses were used to evaluate fibrosis markers (collagen type 1, α-smooth muscle actin).
  • The efficacy of a galectin-3 inhibitor (Gal3i) was tested in the injury model.

Main Results:

  • The model successfully induced tendon fibrosis, characterized by thickening and collagen deposition.
  • Increased expression of collagen type 1 and α-smooth muscle actin confirmed fibrosis.
  • Galectin-3 inhibitor treatment significantly reduced collagen deposition and scarring.

Conclusions:

  • The study presents a reliable model for investigating tendon fibrosis.
  • Galectin-3 inhibition shows promise in overcoming fibrosis associated with tendon injuries.
  • This research could lead to new therapeutic strategies for tendon repair.